No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RPRX240517C25000
- 2.90
- 0.000.00%
15min DelayTrading May 13 16:00 ET
0.00High0.00Low
0.00Open2.90Pre Close0 Volume3 Open Interest25.00Strike Price0.00Turnover0.00%IV-1.69%PremiumMay 17, 2024Expiry Date3.38Intrinsic Value100Multiplier3DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma9.79Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
No Data
News
Express News | Royalty Pharma PLC : Morgan Stanley Raises Target Price to $48.00 From $46.00
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024
Here's What Analysts Are Forecasting For Royalty Pharma Plc (NASDAQ:RPRX) After Its First-Quarter Results
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
Bank of America Securities Keeps Their Buy Rating on Royalty Pharma (RPRX)
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Comments
Unusual items boosting Royalty Pharma's profit may not recur, possibly causing a profit drop this year. The company's statutory earnings may not truly reflect its underlying earnings power. Investors should note 4 warning signs for Royalty Pharma.
There May Be Underlying Issues With The Quality Of Royalty Pharma's (NASDAQ:RPRX) EarningsSignificant insider share selling might worry some shareholders despite the implication of the company acting in all shareholders' interest. The overall analysis of insider transactions, however, lacks confidence.
$Royalty Pharma(RPRX.US$ ur past dur.. lets pop
Read more